|
|
||||||||
Journal of Lipid Research, Vol 28, 292-304, Copyright © 1987 by Lipid Research, Inc.
HJ Harwood Jr, IM Alvarez, YJ Greene, GC Ness and PW Stacpoole
Methods were developed for determination of human mononuclear leukocyte
HMG-CoA reductase protein concentration by a noncompetitive, solid phase,
bridged biotin-avidin enzyme immunoassay procedure. Leukocyte microsomal
HMG-CoA reductase, first immobilized onto a nitrocellulose filter, is
sequentially reacted with 1) monospecific, polyclonal rabbit anti-rat liver
HMG-CoA reductase antiserum, which crossreacts with the human liver and
leukocyte enzymes; 2) biotinylated donkey anti-rabbit immunoglobulin; 3) a
streptavidin-horseradish peroxidase conjugate; and 4) 4-chloro-1-naphthol
and H2O2 to visualize the quantity of horseradish peroxidase bound to the
immunocomplex. Color development was proportional to the quantity of either
purified liver or leukocyte microsomal HMG-CoA reductase applied to the
nitrocellulose. Color development was not observed, however, when HMG-CoA
reductase was omitted from the nitrocellulose, when one of the reactant
species was omitted from the incubation reactions, or when anti-rat liver
HMG-CoA reductase antiserum was pre-absorbed with either rat liver or human
leukocyte HMG-CoA reductase. Immunoreactivity of microsomal HMG-CoA
reductase was independent of the phosphorylation state of the enzyme, but
was inversely related to the concentration of thiol-reducing agents present
in the microsomal preparation up to 4 mM. Further increases in
thiol-reductant failed to produce changes in immunoreactivity. Freshly
isolated mononuclear leukocyte microsomal HMG-CoA reductase protein
concentration in leukocytes from 31 healthy, normocholesterolemic subjects
was a linear function of HMG-CoA reductase activity (R = 0.65; P less than
0.001). The catalytic efficiency of the freshly isolated mononuclear
leukocyte enzyme was 313 +/- 34 pmol of mevalonate formed per min of
incubation at 37 degrees C per mg immunoreactive protein. This methodology,
in conjunction with that recently developed to measure human leukocyte
HMG-CoA reductase activity (1984. J. Lipid Res. 25: 967-978), should prove
useful in discriminating between HMG-CoA reductase regulatory mechanisms
involving changes in enzyme protein concentration and those resulting from
changes in enzyme catalytic efficiency.
ARTICLES
Development of a noncompetitive, solid phase, bridged biotin-avidin enzyme immunoassay for measurement of human leukocyte microsomal HMG- CoA reductase protein concentration
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
T. M. Stulnig, H. Klocker, H. J. Harwood Jr, G. Jurgens, D. Schonitzer, E. Jarosch, L. A. Huber, A. Amberger, and G. Wick In Vivo LDL Receptor and HMG-CoA Reductase Regulation in Human Lymphocytes and Its Alterations During Aging Arterioscler. Thromb. Vasc. Biol., July 1, 1995; 15(7): 872 - 878. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |